Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.

Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Abstract Text:

Pacher,Csaba , Pacher,Csaba , Pacher,Csaba ,Pál Pacher,Csaba Szabó,

Accumulating evidence suggests that the reactive oxygen and nitrogen species are generated in cardiomyocytes and endothelial cells during myocardial ischemia/reperfusion injury, various forms of heart failure or cardiomyopathies, circulatory shock, cardiovascular aging, diabetic complications, myocardial hypertrophy, atherosclerosis, and vascular remodeling following injury. These reactive species induce oxidative DNA damage and consequent activation of the nuclear enzyme poly(ADP-ribose) polymerase 1 (PARP-1), the most abundant isoform of the PARP enzyme family. PARP overactivation, on the one hand, depletes its substrate, NAD+, slowing the rate of glycolysis, electron transport, and ATP formation, eventually leading to the functional impairment or death of the endothelial cells and cardiomyocytes. On the other hand, PARP activation modulates important inflammatory pathways, and PARP-1 activity can also be modulated by several endogenous factors such as various kinases, purines, vitamin D, thyroid hormones, polyamines, and estrogens, just to mention a few. Recent studies have demonstrated that pharmacological inhibition of PARP provides significant benefits in animal models of cardiovascular disorders, and novel PARP inhibitors have entered clinical development for various cardiovascular indications. Because PARP inhibitors can enhance the effect of anticancer drugs and decrease angiogenesis, their therapeutic potential is also being explored for cancer treatment. This review discusses the therapeutic effects of PARP inhibitors in myocardial ischemia/reperfusion injury, various forms of heart failure, cardiomyopathies, circulatory shock, cardiovascular aging, diabetic cardiovascular complications, myocardial hypertrophy, atherosclerosis, vascular remodeling following injury, angiogenesis, and also summarizes our knowledge obtained from the use of PARP-1 knockout mice in the various preclinical models of cardiovascular diseases.

Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Publishing Authors By Initials

P Pacher,C ,P Pacher,C ,P Pacher,C ,P Pacher,C Szabó,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Intr

Journal: Cardiovascular drug reviews

VOLUME: 25

Page Numbers: 235-60

Journal Abbreviation:

ISSN: 0897-5957

DAY: 8

MONTH: 10

YEAR: 2007

Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9006912

Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.

AFFILIATION: Section on Oxidative Stress and Tissue Injury, Laboratory of Physiological Studies, National Institutes of Health, NIAAA, Bethesda MD 20892-9413, USA. pacher@mail.nih.gov

Country: United States

AGENCY: United States NIGMS

GRANT: R01 GM060915

ACRONYM: GM

MEDLINETA: Cardiovasc Drug Rev

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Role of polyADP-ribose polymerase 1 PARP-1 in cardiovascular diseases: the therapeutic potential of PARP inhibitors Related Publications

• 5'- O -Demethylnarcotine: A New Alkaloid from Papaver somniferum.
• A phase I study of myo-inositol for lung cancer chemoprevention.
• A time-resolved fluorescence study of 4',6'-diamidine-2-phenylindole dihydrochloride binding to polynucleotides.
• Activation of poly(ADP-ribose) polymerase by myocardial ischemia and coronary reperfusion in human circulating leukocytes.
• Activation of the poly(ADP-ribose) polymerase pathway in human heart failure.
• Acute alcohol activates STAT3, AP-1, and Sp-1 transcription factors via the family of Src kinases to promote IL-10 production in human monocytes.
• Antiandrogenic effect of isotretinoin: Is the retina involved in mechanism of action?
• Bipolar saline TURP for large prostate glands.
• Characterization of Staphylococcus aureus strains isolated from bovine milk in Hungary.
• Competing associations in bacterial warfare with two toxins.
• Computer-aided spectrophotometric determination of multicomponent drugs.
• Cosegregation of gastrointestinal ulcers and schizophrenia in a large national inpatient discharge database: revisiting the "brain-gut axis" hypothesis in ulcer pathogenesis.
• Critical role of toll-like receptors and the common TLR adaptor, MyD88, in induction of granulomas and liver injury.
• Effects of 7-ketocholesterol on the activity of endothelial poly(ADP-ribose) polymerase and on endothelium-dependent relaxant function.
• Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection.
• Local administration of the poly(ADP-ribose) polymerase inhibitor INO-1001 prevents NAD+ depletion and improves water maze performance after traumatic brain injury in mice.
• Long-term outcomes of dorsal intercarpal ligament capsulodesis for chronic scapholunate dissociation.
• MUC1 is a novel marker for the type II pneumocyte lineage during lung carcinogenesis.
• Model-Based Receptor Quantization Analysis for PET Parametric Imaging.
• Oxidant-induced cardiomyocyte injury: identification of the cytoprotective effect of a dopamine 1 receptor agonist using a cell-based high-throughput assay.
• Petasis Borono-Mannich reaction and allylation of carbonyl compounds via transient allyl boronates generated by palladium-catalyzed substitution of allyl alcohols. an efficient one-pot route to stereodefined alpha-amino acids and homoallyl alcohols.
• Poly(ADP-Ribose) polymerase inhibition improves endothelial dysfunction induced by hypochlorite.
• Poly(ADP-ribose) polymerase inhibition improves endothelial dysfunction induced by reactive oxidant hydrogen peroxide in vitro.
• Ribonucleoprotein-masked nicks at 50-kbp intervals in the eukaryotic genomic DNA.
• Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.
• Single dose treatment with PARP-inhibitor INO-1001 improves aging-associated cardiac and vascular dysfunction.
• Single nucleotide polymorphism: is it only genetic palmistry?
• Single-molecule FRET with diffusion and conformational dynamics.
• The association between the anti-inflammatory protein CC10 and smoking status among participants in a chemoprevention trial.
• Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection.